💡Purolite and Repligen are partnering to develop advanced chromatography resins for the purification of mAbs.🔬
💊This collaboration will focus on creating novel resins that offer higher efficiency and selectivity in the purification process.💪
💼The partnership aims to provide biopharmaceutical manufacturers with improved purification solutions for mAbs production.💼
🌐Purolite’s expertise in resin technology combined with Repligen’s experience in bioprocessing will contribute to the development of innovative resins.💡
💉These new affinity resins have the potential to enhance the efficiency and productivity of mAbs purification, benefiting the biotechnology industry.💪🔬
Introduction:
This article discusses a partnership between Purolite and Repligen to develop affinity resins for the purification of monoclonal antibodies (mAbs). Affinity chromatography is widely used in the downstream processing of biopharmaceuticals, and the collaboration aims to develop new and improved resins that can provide higher purification yields and better cost-efficiency.
- Purolite and Repligen are partnering to develop affinity resins for the purification of monoclonal antibodies (mAbs).
- Affinity chromatography is a key technique in the downstream processing of biopharmaceuticals.
- The partnership aims to improve the performance and cost-efficiency of affinity resins.
- The collaboration will combine Purolite’s expertise in polymer manufacturing and Repligen’s knowledge in affinity ligand design.
- This development has the potential to enhance the purification process for mAbs and improve the overall efficiency of biopharmaceutical production.
Conclusion:
The partnership between Purolite and Repligen to develop affinity resins for the purification of mAbs has the potential to enhance the purification process and improve the efficiency of biopharmaceutical production. This collaboration brings together the expertise of both companies in polymer manufacturing and affinity ligand design, which could lead to the development of new and improved resins with higher purification yields and better cost-efficiency. This advancement could greatly benefit the global biotechnology industry by providing more efficient purification methods for mAbs.
